These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1301588)

  • 21. Intravesical BCG therapy in patients with superficial bladder tumors.
    Steg A; Belas M; Leleu C; Boccon-Gibod L
    Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
    [No Abstract]   [Full Text] [Related]  

  • 22. Superficial bladder disease: case studies and therapeutic advances.
    Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
    Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
    [No Abstract]   [Full Text] [Related]  

  • 23. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Squamous cell carcinoma of the urinary bladder after intravesical bacillus Calmette-Guerin therapy for carcinoma in situ: a case report].
    Uemura M; Nishimura K; Nakagawa M; Kanno N; Miyoshi S; Kawano K; Inoue H
    Hinyokika Kiyo; 2004 Nov; 50(11):809-11. PubMed ID: 15628544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.
    Lamm DL
    Oncology (Williston Park); 1995 Oct; 9(10):947-52, 955, discussion 955-65. PubMed ID: 8573479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 29. Percutaneous BCG perfusion of the upper urinary tract for carcinoma in situ.
    Studer UE; Casanova G; Kraft R; Zingg EJ
    Prog Clin Biol Res; 1989; 310():207-12. PubMed ID: 2771994
    [No Abstract]   [Full Text] [Related]  

  • 30. Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments.
    Jauhiainen K; Rintala E
    Ann Chir Gynaecol Suppl; 1993; 206():31-8. PubMed ID: 8291866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
    van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
    Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of superficial carcinoma of the bladder.
    Paulson DF
    Prog Clin Biol Res; 1984; 162B():193-209. PubMed ID: 6209720
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
    Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
    Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
    [No Abstract]   [Full Text] [Related]  

  • 34. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
    Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
    Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
    J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
    Palou J; Xavier B; Laguna P; Montlleó M; Vicente J
    Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
    Fisher HA
    Prog Clin Biol Res; 1989; 310():275-83. PubMed ID: 2505271
    [No Abstract]   [Full Text] [Related]  

  • 38. [Percutaneous Bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ].
    Yamashita S; Yogi Y; Taniguchi K; Morimitsu H; Suzu H; Kanetake H; Saito Y; Kubota S
    Hinyokika Kiyo; 1992 Oct; 38(10):1095-9. PubMed ID: 1481770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
    Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granulomatous hepatitis following intravesical BCG therapy.
    Thompson D; Cumming J
    Br J Urol; 1990 Oct; 66(4):432-3. PubMed ID: 2224441
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.